Mineralys Therapeutics, Inc.

NASDAQ:MLYS

Biotechnology

Healthcare
$13.78 +1.49%

+$0.37 today

Market cap
$1.22B
Beta
0.56
P/E (TTM)
-13.9
EPS (TTM)
-$1.83
52W Low $12.59High $47.65

Volume 1.39M

Average 1.48M

MLYS Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Mineralys Therapeutics, Inc.NASDAQ: MLYS

Free Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Free cash flow growth accelerates

Q2 FY2026 free cash flow of $32.56M (cash outflow) rose 7.9% year over year, ahead of the -28.0% change in trailing-twelve-month free cash flow. Sequentially, it fell 17.5% from the prior quarter. Over 3 fiscal years it compounded at +69.6% a year.

Context

  • Free cash flow grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +7.9% holds above the trailing-twelve-month pace of -28.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$32.56M-17.5% QoQ
Last fiscal yearDec 2025
-$142.43M-14.4% YoY
LTMJun 2026
-$138.8M-28.0% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.9%——
1 year-14.4%——
3-year CAGR+69.6%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(142.43M) USD
Year-over-year change
+14.4%

Free Cash Flow vs competitors

How MLYS compares with its peers on the latest reported figures

  • MLYS's LTM Jun 2026 free cash flow of $138.8M is the 2nd largest of the 7 companies compared; the peer median is $43.08M.
  • Its year-over-year change of -28.0% is the 6th highest of 7, against a peer median of +19.3%.
  • Over three fiscal years its annual growth of +69.6% compares with a peer median of +22.2%.
MLYS Competitors Peer median
Free Cash Flow for MLYS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VERAVera Therapeutics, Inc.LTM Jun 2026$339.06M +81.8%+52.9%—
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$138.8M -28.0%+69.6%—
TVTXTravere Therapeutics, Inc.LTM Sep 2026$134.22M +267.1%-54.4%20.6%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$122.13M -277.7%+3.7%610.6%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$55.08M +1.1%+18.3%168.3%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$31.09M +37.5%+35.9%—
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$28.67M -7.8%+26.0%—
Peer median (excluding MLYS) $43.08M+19.3%+22.2%168.3%

Competitors are the stored peer set for MLYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(19.41M)(29.8M)(71.9M)(177.81M)(154.65M)
Depreciation & Amortization00043K59K
Deferred Income Tax00000
Stock-Based Compensation80K455K5.06M11.34M19.32M
Change in Working Capital4.09M772K(7.47M)9.52M2.73M
Accounts Receivables00(355K)424K(166K)
Inventory00000
Accounts Payables00000
Other Working Capital4.09M772K(7.12M)9.1M2.9M
Other Non-Cash Items684K(649K)(6.87M)(9.41M)(9.88M)
Operating Cash Flow(14.56M)(29.22M)(81.17M)(166.31M)(142.42M)
Capital Expenditures000(96K)(15K)
Acquisitions (Net)00000
Purchases of Investments0(71.76M)(347.97M)(373.45M)(814.74M)
Sales of Investments050M187.5M488.5M425M
Other Investing Activities00000
Investing Cash Flow0(21.76M)(160.47M)114.96M(389.75M)
Debt Repayment00000
Common Stock Issued23.81M0202.99M116.06M591M
Common Stock Repurchased0(1.63M)000
Dividends Paid00000
Other Financing Activities00258K83K0
Financing Cash Flow23.81M128.02M203.25M116.14M591M
Effect of Forex Changes00000
Net Change in Cash9.25M77.04M(38.4M)64.79M58.83M
Free Cash Flow(14.56M)(29.22M)(81.17M)(166.41M)(142.43M)

Mineralys Therapeutics, Inc.

NASDAQ:MLYS

Intrinsic Alpha fair value

Locked

Current Price

$13.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.